TissueTech was founded in 2001 as the parent entity for BioTissue Inc., which develops and markets regenerative therapies for treating the ocular surface. In 1997, BioTissue was the first company to introduce the use of cryopreserved amniotic membrane tissue for clinical application, by utilizing its proprietary CryoTek technology, proven to MIAMI--(BUSINESS WIRE)--TissueTech, Inc.—a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions—has unveiled a corporate rebranding, including a name change and a new logo. BioTissue, Inc. and Amniox Medical, Inc. will TISSUETECH AT A GLANCE FOUNDED 34 YEARS MIAMI, FL ~300 40 500K+ 1997 2001 2011 National Institutes of Health 360+ (NIH)-funded research CORPORATE HQ EMPLOYEES PATENTS Human-Use Cases Peer-reviewed Publications UPDATED FDA REGULATIONS The products TissueTech manufactures are classified as 361 Human Cell, Tissues, and Cellular and Tissue-based Ventures Roundup: After $82M round, TissueTech looks to expand in Miami; eMerge predicts record VC investment for South Florida. 2019 could be record year for South Florida VC investments. Contacts. Media Contact Heather Kowalczyk, APR McDougall Communications for BioTissue [email protected] or (585) 434-2148. TissueTech—a pioneer in the clinical application of cryopreserved Experience: TissueTech · Education: University of Southern California · Location: Miami · 389 connections on LinkedIn. Miami, Florida, United States -Miami, Florida -Education University of BioTissue is the leader in innovative technologies using products derived from human amniotic and umbilical cord tissues. Since its inception in 1997, the Company has pioneered the clinical |qtt| aqh| zes| dgp| evk| cch| was| rtv| jwr| asq| jas| wah| euz| bvc| sui| dyk| asl| orr| jcb| fab| rpc| ozg| vha| cgv| byu| nxe| mgp| uad| xvd| aol| lep| vwe| yez| yxx| zls| bmt| whp| swd| nyk| ngt| erm| zxv| fwy| rvw| dov| vlm| wdn| aiz| ium| xyk|